Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) Sees Large Growth in Short Interest

Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) was the recipient of a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 8,100 shares, an increase of 406.3% from the December 31st total of 1,600 shares. Based on an average daily trading volume, of 356,600 shares, the days-to-cover ratio is currently 0.0 days.

Enzon Pharmaceuticals Stock Performance

Enzon Pharmaceuticals stock traded down $0.00 during mid-day trading on Tuesday, hitting $0.13. The company’s stock had a trading volume of 3,840 shares, compared to its average volume of 91,967. The company has a 50 day moving average of $0.13 and a 200-day moving average of $0.13. Enzon Pharmaceuticals has a one year low of $0.06 and a one year high of $0.24. The stock has a market cap of $9.51 million, a PE ratio of 12.83 and a beta of 0.27.

Enzon Pharmaceuticals Company Profile

Enzon Pharmaceuticals, Inc, together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs.